Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
five-phage anti-staphylococcus aureus bacteriophage cocktail
- Development stage
- Unknown
- Lead developer
- University of Calgary
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intraarticular, Intravenous
01
Overview
The five-phage anti-staphylococcus aureus bacteriophage cocktail is an experimental biologic therapy consisting of five distinct lytic bacteriophages specifically selected for their activity against *Staphylococcus aureus*. Developed and evaluated by researchers at the University of Calgary, this cocktail is designed to treat complex, biofilm-associated infections such as prosthetic joint infections (PJI). The mechanism of action involves the phages' ability to recognize, bind to, and inject their genetic material into target staphylococcal cells, leading to viral replication and subsequent bacterial cell lysis. While primarily targeted at *S. aureus*, the cocktail has demonstrated clinical utility against other staphylococcal species, including *Staphylococcus lugdunensis*, in salvage therapy settings where conventional antibiotics and surgical interventions have failed. The treatment regimen typically involves both local intra-articular injections and systemic intravenous administration to ensure comprehensive eradication of the pathogen.
- Other names
- five-phage cocktailanti-staphylococcus aureus bacteriophage cocktailStaphylococcus aureus bacteriophage cocktail
02
Targets
WTA (Staphylococcus lugdunensis wall teichoic acid)PGN (Staphylococcus lugdunensis peptidoglycan)PGN (Peptidoglycan)TA (Teichoic acid)
Beyond the preview
Go deeper on five-phage anti-staphylococcus aureus bacteriophage cocktail.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on five-phage anti-staphylococcus aureus bacteriophage cocktail.